Kidokoro and co-workers suggested the negative regulation of Cdc20 by p53 to explain the elevation of Cdc20 level in p53-deficient cells and proposed Cdc20 protein as a potential cancer therapeutic target50. This evidence concerns the gene CDC20 and cancer.